Cynapsus Therapeutics Inc. : Announces Proposed Public Offering in the United States, Listing on NASDAQ and Share Consolidation
GlobeNewswire - Fri May 15, 4:33PM CDT
Cynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAF) announced today the filing of a registration statement with the US Securities and Exchange Commission relating to a public offering in the United States of its common shares and the filing of an application to list on the NASDAQ Capital Market. The timing, number of shares and price per share of the proposed offering have not yet been determined. Cynapsus also announced an amendment to the Company's articles to consolidate the issued and outstanding common shares of the Company on the basis of one post-consolidation common share for 16 pre-consolidation common shares to facilitate the proposed listing on NASDAQ, as previously approved by the shareholders of the Company.
CTH.TO: 21.97 (-0.97)
Cynapsus Therapeutics Announces Proposed Public Offering in the United States, Listing on NASDAQ and Share Consolidation
Marketwired - Fri May 15, 4:29PM CDT
Cynapsus Therapeutics Inc. (TSX: CTH)(OTCQX: CYNAF) announced today the filing of a registration statement with the US Securities and Exchange Commission relating to a public offering in the United States of its common shares and the filing of an application to list on the NASDAQ Capital Market. The timing, number of shares and price per share of the proposed offering have not yet been determined. Cynapsus also announced an amendment to the Company's articles to consolidate the issued and outstanding common shares of the Company on the basis of one post-consolidation common share for 16 pre-consolidation common shares to facilitate the proposed listing on NASDAQ, as previously approved by the shareholders of the Company.
CTH.TO: 21.97 (-0.97)
Cynapsus Therapeutics Reports First Quarter 2015 Financial Results and Recent Developments
Marketwired - Fri May 08, 3:46PM CDT
Cynapsus Therapeutics Inc. (TSX: CTH)(OTCQX: CYNAF), a specialty Central Nervous System (CNS) pharmaceutical company developing and preparing to commercialize a fast-acting, easy-to-use sublingual thin film for the on-demand management of debilitating OFF episodes associated with Parkinson's disease (PD), today announced financial results for the three months ended March 31, 2015. Unless specified otherwise, all amounts are in Canadian dollars.
CTH.TO: 21.97 (-0.97)
Cynapsus Therapeutics Announces CAD$21 Million Private Placement
BusinessWire - Tue Mar 31, 9:26AM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, today announced the completion of a private placement (the "Offering"
CTH.TO: 21.97 (-0.97)
Cynapsus Therapeutics Reports 2014 Annual Results
BusinessWire - Tue Mar 17, 4:56PM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, today announced financial results for the year ended December 31, 2014. Unless specified otherwise, all amounts are in Canadian dollars.
CTH.TO: 21.97 (-0.97)
Cynapsus to Host Analyst and Investor Breakfast in New York City on March 18
BusinessWire - Mon Mar 16, 5:00AM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on Parkinson's disease, announced that it will host an Analyst and Investor Breakfast featuring presentations by executive management and a clinical key opinion leader on Wednesday, March 18, 2015 at 7:30 a.m. in New York City.
CTH.TO: 21.97 (-0.97)
Cynapsus Therapeutics Appoints Tamar Howson to Board of Directors
BusinessWire - Thu Mar 12, 3:10PM CDT
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on the treatment of OFF episodes in Parkinson's disease, today announced that Tamar Howson has been appointed to the Company's Board of Directors. With the addition of Ms. Howson to the Board of Directors, the Company now has eight directors, with seven directors classified as independent.
OXGN: 0.70 (-0.03), NPSP: 45.97 (+0.01), BMY: 75.06 (-0.50), CTH.TO: 21.97 (-0.97)
Cynapsus Therapeutics Provides Clinical and Regulatory Update for APL-130277 for the Acute Rescue of OFF Motor Symptoms of Parkinson's Disease
BusinessWire - Wed Mar 11, 3:10PM CDT
--Received Final Minutes From End-of-Phase 2 Meeting with U.S. FDA
CTH.TO: 21.97 (-0.97)
Cynapsus Therapeutics Inc. to Present at the D2 2015 - Noble Financial Capital Markets' Eleventh Annual Investor / Equity Conference
BusinessWire - Thu Jan 15, 3:05PM CST
Cynapsus Therapeutics Inc. (TSX:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company, today announced that its President and CEO, Anthony Giovinazzo, will present at the Noble Financial Capital Markets' Eleventh Annual Equity Conference at Club Med in Sandpiper Bay, Florida, on Monday, January 19th at 10:00am Eastern Standard Time in Room 1.
CTH.TO: 21.97 (-0.97)
Cynapsus Therapeutics Announces Uplisting to the Toronto Stock Exchange's Senior Equity Market
BusinessWire - Tue Nov 25, 3:10PM CST
Cynapsus Therapeutics Inc. (TSX-V:CTH) (OTCQX:CYNAF), a specialty pharmaceutical company focused on Parkinson's disease, today announced that its common shares will commence trading on the Toronto Stock Exchange (TSX) as of the opening of trading on Friday, November 28, 2014. The Company's common shares will continue to trade under the symbol "CTH," with its common shares to cease trading on the TSX Venture Exchange concurrent with the commencement of trading on the TSX.